ARS Pharmaceuticals
SPRY· Manufacturing· Fiscal year ends in December
Richard Lowenthal, M.S., MSEL is the CEO of ARS Pharmaceuticals.
Executives3
See all- 1Justin ChakmaChief Business OfficerFY2025
- 2Sarina Tanimoto, M.D., M.B.A.Chief Medical OfficerFY2022
- 3Richard Lowenthal, M.S., MSELPresident and Chief Executive OfficerNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allARS Pharmaceuticals paid its one named executive on file $2.9M in FY2025 (Dec).
| Name | ||
|---|---|---|
| Justin ChakmaChief Business Officer | Not disclosed | |
| Sarina Tanimoto, M.D., M.B.A.Chief Medical Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe FY2025 (Dec) proxy of ARS Pharmaceuticals names 18 peer companies for pay. Among ARS Pharmaceuticals and these peers, CEO pay was 5th highest of 8 and total shareholder return was 5th highest of 8.
5th highest of 8in ARS Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:
5th highest of 8in ARS Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board5
See all- Pratik Shah, Ph.D.Chair · 9 yr on the boardNot independent—Paid as an executive
- Michael KellyDirector · 6 yr on the boardIndependentAudit, Commercial—Paid as an executive
- Brenton L. SaundersDirector · 4 yr on the boardIndependentCommercial (Chair)—Paid as an executive
- Peter Kolchinsky, Ph.D.Director · 4 yr on the boardIndependentNominating and Corporate Governance (Chair)—Paid as an executive
- Rajeev DadooDirector · 4 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2025).
Activity
No new filings about this company in the feed.
Filings6
See all| Proxy statement | DEF 14A | Apr 29, 2026 | FY2025 |
| Annual report | 10-K | Mar 9, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |
| Annual report | 10-K | Mar 20, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 21, 2024 | FY2023 |
